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Background: Convolutional neural networks (CNNs) efficiently differentiate skin lesions by image analysis. Studies
comparing a market-approved CNN in a broad range of diagnoses to dermatologists working under less artificial
conditions are lacking.
Materials and methods: One hundred cases of pigmented/non-pigmented skin cancers and benign lesions were used
for a two-level reader study in 96 dermatologists (level I: dermoscopy only; level II: clinical close-up images,
dermoscopy, and textual information). Additionally, dermoscopic images were classified by a CNN approved for the
European market as a medical device (Moleanalyzer Pro, FotoFinder Systems, Bad Birnbach, Germany). Primary
endpoints were the sensitivity and specificity of the CNN’s dichotomous classification in comparison with the
dermatologists’ management decisions. Secondary endpoints included the dermatologists’ diagnostic decisions, their
performance according to their level of experience, and the CNN’s area under the curve (AUC) of receiver operating
characteristics (ROC).
Results: The CNN revealed a sensitivity, specificity, and ROC AUC with corresponding 95% confidence intervals (CI) of
95.0% (95% CI 83.5% to 98.6%), 76.7% (95% CI 64.6% to 85.6%), and 0.918 (95% CI 0.866e0.970), respectively. In level I,
the dermatologists’ management decisions showed a mean sensitivity and specificity of 89.0% (95% CI 87.4% to 90.6%)
and 80.7% (95% CI 78.8% to 82.6%). With level II information, the sensitivity significantly improved to 94.1% (95% CI
93.1% to 95.1%; P < 0.001), while the specificity remained unchanged at 80.4% (95% CI 78.4% to 82.4%; P ¼ 0.97).
When fixing the CNN’s specificity at the mean specificity of the dermatologists’ management decision in level II
(80.4%), the CNN’s sensitivity was almost equal to that of human raters, at 95% (95% CI 83.5% to 98.6%) versus
94.1% (95% CI 93.1% to 95.1%); P ¼ 0.1. In contrast, dermatologists were outperformed by the CNN in their level I
management decisions and level I and II diagnostic decisions. More experienced dermatologists frequently
surpassed the CNN’s performance.
Conclusions: Under less artificial conditions and in a broader spectrum of diagnoses, the CNN and most dermatologists
performed on the same level. Dermatologists are trained to integrate information from a range of sources rendering
comparative studies that are solely based on one single case image inadequate.
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Computer-aided diagnostic (CAD) systems for the detection
of skin cancer have been developed and approved for market
access.1 Understandably, CAD systems for automated classi-
fication of lesions2e5 have been trained to attain high sen-
sitivities (>90%); however, mostly at the cost of low
specificities.6https://doi.org/10.1016/j.annonc.2019.10.013 137
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detection of hand-engineered segmentation features have
been overcome by applying convolutional neural networks
(CNNs). CNNs are commonly trained by ‘supervised deep
learning’, an end-to-end approach using raw image data and
corresponding diagnostic labels. Within the network,
specialized filters autonomously assess input images on a
pixel level for good representations of the true diagnosis.
Each additional training image improves the CNN’s ability to
assemble and weight features associated with the diagnosis.
Most studies investigating CNNs in skin cancer classifi-
cation tasks have shown performance at or above the level
of dermatologists.7e12 Prospective studies are still lacking
and the experimental design of previous studies was criti-
cized for being highly artificial on the side of dermatologists,
thus not reflecting results expected in a real-life clinical
setting.13 With the intention to create a head-to-head
comparison of CNNs and dermatologists, studies granted
access to only one dermoscopic or clinical image per case.
Whereas the CNNs were trained to make a classification
based on a single image, dermatologists are used to inte-
grating information from various sources (e.g. patient’s risk
profile, anamnestic data, lesion evolution). Moreover, many
earlier studies focused on a limited spectrum of diagnoses
(i.e. nevi versus melanomas).9,10,12 Although this approach
may be useful for an initial proof of concept, it does not
adequately reflect the clinical situation where dermatolo-
gists encounter a much broader spectrum of lesions. Finally,
most previous publications did not specify a commercially
or publicly available CNN architecture making it difficult to
reproduce reported results.
The study presented herein was designed to (partly)
overcome the aforementioned limitations by including a
broad spectrum of pigmented and non-pigmented skin le-
sions to be classified by the current version of a commer-
cially available and market-approved CNN. Moreover,
dermatologists were allowed to work in a more familiar
setting, that is, in a classical store-and-forward tele-
dermatology setting.14 This meant using the dermatologists’
management decision based on the combination of clinical
close-up images, dermoscopic images, and textual case in-
formation as a comparator.MATERIALS AND METHODS
The ethics committee of the medical faculty of the Univer-
sity of Heidelberg approved this study (approval number
S-629/2017), which was conducted in accordance with the
Declaration of Helsinki principles. The CNN used in this study
is the current market version of Moleanalyzer Pro (Foto-
Finder Systems GmbH, Bad Birnbach, Germany), a CNN ar-
chitecture based on a modified version of Google’s
Inception_v4,15 specifically trained by dermoscopic images
and approved as a medical device in the European Union
(Conformité Européenne mark). The prototype of the CNN
(supplementary Figure S1, available at Annals of Oncology
online) was originally developed by a cooperative con-
sortium of industry and academia (with the participation of138 https://doi.org/10.1016/j.annonc.2019.10.013HAH) and tested in a pivotal study.9 Details on methods
about the CNN architecture and training are in the
supplementary methods, available at Annals of Oncology
online.
Data for test cases
We created a dataset of 100 cases including pigmented/
non-pigmented and melanocytic/non-melanocytic skin le-
sions (supplementary Table S1, available at Annals of
Oncology online). The images originated from different
body sites including special localizations (e.g. face/scalp,
mucosa, acral skin) and were manually selected by HAH and
CF from a convenience sample collected between 2014 and
2019. Each test case included (i) one clinical close-up image,
(ii) one dermoscopic image, (iii) textual case information
(patient age, sex, and location of the lesion), and (iv) un-
equivocal histopathological diagnosis for excised lesions (all
malignant lesions, 75% of benign lesions) or unremarkable
follow-up data over at least 2 years (25% of benign lesions).
Various camera/dermoscope combinations were used for
image acquisition. No overlap between datasets for
training, validation, and testing was allowed.
The CNN’s performance was also tested in two larger and
publicly available datasets (available at https://www.isic-
archive.com) containing the full spectrum of diagnoses to
confirm the generalizability of the CNN results, namely the
MSK-1 dataset (1100 images) and the ISIC-2018 challenge16
dataset (1511 images). The corresponding diagnoses of the
ISIC-2018 challenge dataset will not be released by the or-
ganizers, which necessitated external statistical analyses by
one of the authors (PT).
Reader study level I and II
Dermatologists were personally invited to participate via a
web-based rating application. Participants’ data were de-
identified and categorized according to self-reported levels
of experience with dermoscopy (beginner, <2 years of
experience; skilled, 2e5 years of experience; expert, 5
years of experience).
Each case included two subsequent computer slides, (i)
dermoscopic image (level I information) and (ii) dermo-
scopic image plus clinical close-up image and textual case
information (level II information). Dermatologists were
asked to indicate their management decision (treatment/
excision, no action, follow-up examination) and dichoto-
mous diagnosis (malignant/premalignant, benign) for each
slide.
Statistical analysis
The primary outcome measures were the CNN’s sensitivity
and specificity in comparison with the dermatologists’
management decisions in study level I and II. Secondary
endpoints included the dermatologists’ diagnostic de-
cisions, their performance according to their experience,
and the CNN’s area under the curve (AUC) of receiver
operating characteristics (ROC). Estimates are provided
along with 95% confidence intervals.Volume 31 - Issue 1 - 2020
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amination’ were considered true-negative for benign le-
sions. Actinic keratosis (AK) shows limited potential to
progress to invasive carcinoma and ‘excision/treatment’ and
‘follow-up examination’ were considered as true-positive.
The CNN’s softmax layer gave a malignancy score ranging
from 0 to 1 with the a priori cutoff of >0.5 for classifying a
lesion as being malignant.
The CNN’s performance was compared with dermatolo-
gists’ by using their mean specificity to determine the
corresponding cutoff in CNN malignancy scores within a 400-
image validation set. This cutoff was applied to the test set
and the resulting CNN’s sensitivity was then compared with
the average sensitivity of dermatologists by a two-sided one-
sample t-test. We further applied the non-parametric
KruskaleWallis test as an omnibus test of heterogeneity
between dermatologists with different levels of experience
and carried out post hoc comparisons of any pair of levels
using the Dunn-Nemenyi procedure to adjust for multiple
comparisons.17 Changes in dermatologists’ diagnostic per-
formance after receiving level I or level II information were
tested by the Wilcoxon paired signed-rank test with obser-
vations related to readers. The results were considered sta-
tistically significant at the P < 0.05 level due to the
observational nature of the investigation. All analyses were
carried out using SPSS version 24 (IBM, SPSS, Chicago, IL) or
SAS/STAT software, version 9.4 (SAS Institute Inc., Cary, NC).
RESULTS
CNN’s diagnostic performance
In its current market configuration (June 2019), the CNN
showed a sensitivity and specificity of 95.0% [95% confi-
dence interval (CI) 83.5% to 98.6%] and 76.7% (95% CI
64.6% to 85.6%), respectively. The ROC AUC was 0.918 (95%
CI 0.866e0.970) (Figure 1). Boxplots in Figure 2 show the
distribution of malignancy scores in relation to diagnostic
categories. With the a priori malignancy cutoff at >0.5, the
percentage of correct classifications in malignant lesions
was 100% in AK, 100% in Bowen’s disease, 100% in mela-
noma, 100% in basal cell carcinomas (BCCs), and 60% in
squamous cell carcinomas (SCCs). In benign lesions, the
percentage of correct classifications was 90% in nevi, 80% in
angioma/angiokeratoma, 70% in seborrheic keratoses, 60%
in dermatofibroma, and 50% in solar lentigo.
In order to rule out overfitting and to confirm the
generalizability of our results, two larger external datasets
were used for testing (supplementary Figure S2, available at
Annals of Oncology online), namely MSK-1 (1100 images)
and ISIC-2018 challenge (1511 images). In the MSK-1
datasets the CNN attained an almost identical perfor-
mance in comparison to our test set (sensitivity 94.2%,
specificity 73.8%, ROC AUC 0.939). In the ISIC-2018 chal-
lenge dataset the CNN showed a lower sensitivity of 84.7%
at a higher specificity of 84.1% and a comparable ROC AUC
of 0.926. The pairwise comparison of ROC AUCs attained by
the CNN in all three datasets revealed no significant dif-
ferences (all P > 0.527).Volume 31 - Issue 1 - 2020Diagnostic performance of dermatologists
Dermatologists (N ¼ 96) were categorized into beginners
(n ¼ 17, <2 years of experience), skilled (n ¼ 29, 2e5 years
of experience), and experts (n ¼ 40, >5 years of experi-
ence). Ten participants did not provide information. The
mean diagnostic performance of the dermatologists was
assessed for their management decisions and dichotomous
diagnostic classification of lesions in level I and II (Table 1).
Management decisions. The mean sensitivity and specificity
of dermatologists for management decisions during study
level I (dermoscopy only) was 89.0% (95% CI 87.4% to
90.6%) and 80.7% (95% CI 78.8% to 82.6%), respectively
(Table 1). With additional case information in level II the
sensitivity significantly improved to 94.1% (95% CI 93.1% to
95.1%; P < 0.001) while the specificity stayed largely un-
changed (80.4%, 95% CI 78.4% to 82.4%; P ¼ 0.97).
As expected, the performance of dermatologists improved
with more experience (supplementary Table S2, available at
Annals of Oncology online). In level I, the percentage of
correct management decisions (accuracy) increased from
79.9% in beginners (95% CI 77.7% to 82.1%) to 83.3% in
skilled (95% CI 80.1% to 85.6%) and 86.9% in experts (95% CI
85.5% to 88.3%). Similar observations were made for differ-
ences in sensitivity and specificity. The comparison of all
three groups was significant for accuracy (P < 0.001) and
specificity (P¼ 0.005).When applying pairwise comparisons,
significant differences in diagnostic performance were only
observed for accuracy when comparing experts with begin-
ners (P ¼ 0.006). The sample was too small to attain signifi-
cance for the observed trend regarding sensitivity (P¼ 0.108,
all group comparison).The same observations weremade for
accuracy in level II [beginners: 82.0% (95% CI 79.3% to
84.7%), skilled: 85.4% (95% CI 83.0% to 87.8%), experts:
88.5% (95% CI 87.0% to 90.0%)]. However, in level II, the
differences between experts and beginners were also sig-
nificant for specificity (P ¼ 0.029), while significance for
sensitivity was still missed (P ¼ 0.225).
Dichotomous diagnostic classification. When viewing one
dermoscopic image per case (study level I), the 96 derma-
tologists achieved a mean sensitivity and specificity for the
dichotomous diagnostic classification of 83.8% (95% CI
81.8% to 85.8%) and 77.6% (95% CI 75.2% to 80.0%),
respectively. With more information in level II, the sensi-
tivity significantly improved to 90.6% (95% CI 89.3% to
92.0%; P < 0.001). In contrast with management decisions,
the specificity also significantly increased to 82.4% (95% CI
80.5% to 84.3%; P < 0.001).
In level I, the percentage of correct dichotomous clas-
sifications increased with more experience from 72.6% in
beginners (95% CI 67.6% to 77.6%) to 79.3% in skilled
(95% CI 76.3% to 82.3%) to 84.2% in experts (95% CI
82.0% to 86.4%) (all P < 0.01; supplementary Table S2,
available at Annals of Oncology online). The same obser-
vation was made in level II [beginners: 81.2% (95% CI
78.0% to 84.4%), skilled: 85.1 (95% CI 82.5% to 87.7%),
experts: 88.7% (95% CI 87.0% to 90.4%)]. As shown forhttps://doi.org/10.1016/j.annonc.2019.10.013 139
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Figure 1. ROC curve of the CNN (black curve) in relation to the results of all dermatologists (N [ 96, red dots) in their dichotomous classifications (A: level I, B:
level II) and their management decisions (C: level I, D: level II). The average (± SD) sensitivity and specificity of all dermatologists (mean: green circle; ± SD: green
error bars) and the CNN’s point of operation (blue circle, sensitivity: 95.0%, specificity: 76.7%) is depicted. Dermatologists performed best when allowed to review
more case information (B better than A, D better than C) and when deciding on the management of cases (D better than B).
Annals of Oncology H. A. Haenssle et al.management decisions, significance was attained in the
comparison between groups in terms of accuracy and
specificity (all P < 0.001) driven by differences between
experts and beginners.
Diagnostic performance of CNN versus dermatologists
We used the mean specificity of all dermatologists’ man-
agement decisions in level II (80.4%) as the benchmark for
comparison to the CNN (Figure 1D). To this end, the speci-
ficity of 80.4% was used to attain the CNN’s corresponding a
priori malignancy score cutoff in a 400-image validation set.
At this cutoff, the CNN’s sensitivity in the test set was 95.0%
(95% CI 83.5% to 98.6%), which was similar to the mean
sensitivity of dermatologists [94.1% (95% CI 93.1% to
95.1%); P ¼ 0.1].
140 https://doi.org/10.1016/j.annonc.2019.10.013When management decisions were solely based on one
dermoscopic image per case (level I), the dermatologists’
sensitivity was significantly lower than the CNN’s [89.0%
(95% CI 87.4% to 90.6%) versus 95.0% (95% CI 83.5% to
98.6%); P < 0.001]. Similarly, the CNN showed a superior
sensitivity when compared with the dermatologists’ dichot-
omous classifications in level I [83.8% (95% CI 81.8% to
85.8%); P < 0.001] or II [90.6% (95% CI 89.3% to 92.0%);
P < 0.001]. Figure 1 depicts the performance of dermatolo-
gists during level I and II in comparison with the CNN.
Additionally, we compared the CNN’s accuracy (percent-
age of correct classifications) with the dermatologists’ ac-
curacy (Table 1). When the CNN’s accuracy (84.0% (95% CI
75.6% to 89.9%) was compared with the dermatologists’









































































Figure 2. The CNN’s melanoma probability scores (range 0e1) for major benign and malignant diagnostic categories are depicted as boxplots. Scores closer to 1
indicated a higher probability of malignancy. The upper and lower bounds of boxes indicate the 25th and 75th percentiles, and the median is indicated by the line
intersection of the upper and lower box. Whiskers indicate the full range of probability scores.
BCC, basal cell carcinoma; SCC, squamous cell carcinoma; SebK, seborrheic keratosis.
H. A. Haenssle et al. Annals of Oncology(95% CI 84.7% to 87.1%)] dermatologists performed slightly
but significantly better (P ¼ 0.003).
DISCUSSION
The incidence rates of melanoma and non-melanoma skin
cancers are rising globally in most fair-skinned pop-
ulations.18 Additional efforts in primary and secondary




All (N ¼ 96) 89.0% 80.7% 8
Beginner (n ¼ 17) 85.7% 76.1% 7
Skilled (n ¼ 29) 89.7% 79.1% 8
Expert (n ¼ 40) 91.1% 84.1% 8
Raters level II
All (N ¼ 96) 94.1% 80.4% 8
Beginner (n ¼ 17) 92.9% 74.7% 8
Skilled (n ¼ 29) 94.7% 79.2% 8
Expert (n ¼ 40) 94.8% 84.4% 8
CNN 95.0% 76.7% 8
Level I: readers were provided with dermoscopic images only.
Level II: readers were provided with close-up images and textual case information in addit
Accuracy: calculated as the percentage of correct classifications/decisions ([true-positive þ
Self-reported level of experience was categorized into expert: >5 years of experience; skilled
not report their level of experience.
a The CNN’s accuracy was significantly higher than the mean accuracy of dermatologists.
b The mean accuracy of dermatologists was significantly higher than the CNN’s accuracy.
Volume 31 - Issue 1 - 2020these trends. Previous reports on the application of CNN in
the diagnosis of skin cancer demonstrated performance on
or above the level of dermatologists but were legitimately
criticized for highly artificial study settings.13 Unlike earlier
studies,9,10,16 our test cases included malignant and
benign, melanocytic and non-melanocytic, and pigmented
and non-pigmented skin lesions. This broad range
comprised the vast majority of skin lesions biopsied in theBinary classification
ccuracy Sensitivity Specificity Accuracy
4.0% 83.8% 77.6% 80.1%a
9.9%a 80.0% 67.7% 72.6%a
3.3% 84.3% 75.9% 79.3%a
6.9%b 86.2% 82.9% 84.2%
5.9%b 90.6% 82.4% 85.7%b
2.0% 89.0% 76.0% 81.2%
5.4% 90.9% 81.2% 85.1%
8.5%b 91.8% 86.6% 88.7%b
4.0% 95.0% 76.7% 84.0%
ion to dermoscopic images.
true-negative]/all cases).
: 2e5 years of experience; and beginner: <2 years of experience. Ten participants did
https://doi.org/10.1016/j.annonc.2019.10.013 141
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and brings the setting closer to a real-life clinical situation.
Moreover, our results demonstrate that the amount of
case information and the decisions asked of dermatologists
had a major impact on their performance. Dermatologists
performed best when allowed to review clinical plus der-
moscopic images accompanied by textual metadata. This
setting largely reflects the presentation of cases in classical
store-and-forward teledermatology14 and allows derma-
tologists to integrate different levels of information.
Interestingly, these observations also hold for neural net-
works, as the fusion of two separate CNNs, one assessing
clinical close-up images and the other dermoscopic images
of the same cases, achieved better results than either mo-
dality alone.11 Moreover, the first reports of deep learning
models using clinical non-imaging information have shown
promising results in predicting skin cancer19 and may be
included in neural networks. In their daily routine, derma-
tologists make management decisions rather than clear-cut
classifications whether it be more simple dichotomous
classifications (benign versus malignant) or naming specific
diagnoses. For each probable diagnosis there will be dif-
ferential diagnoses and dermatologists are not used to
ranking these by a probability score. It may be assumed that
conflicting options lead to random decisions. Therefore, for
future studies we recommend giving physicians enough
data for review and to use their management decisions as
the primary outcome. Of note, as the dermatologists’
experience will strongly affect the results of a comparison to
a CNN, we further recommend reporting their performance
ranked by experience.
While the CNN in our present study undoubtedly per-
formed very well, the question of who will benefit the most
from applying a CNN is still a subject of much debate. On
leaving the framework of a clinical study, ‘man against
machine’ becomes ‘man with a machine’ and physicians will
need to incorporate the CNN’s classification into their
decision-making process. Unfortunately, there are no pro-
spective studies available to show the impact of a CNN
assisting dermatologists in their daily clinical work.13
Nevertheless, our summarized data in Table 1 suggest
that less experienced physicians will benefit the most. For
management decisions of highly trained experts with all
case information at hand, our data indicate a possible
decrease in specificity at an unchanged sensitivity should
they strictly follow each of the CNN’s classifications.
Overfitting is an important limitation not well recognized
by many previous CNN-based studies. Overfitting may occur
when using an image dataset collected from a few sources
that is randomly split into training versus validation and
testing. A similarly narrow distribution of lesions for training
and testing may result in an overestimation of the CNN’s
performance and lackof generalizability.16 In our study setting
we can safely rule out overfitting because training images
were collected from multiple sources around the world and
test cases were derived from sources that did not provide
training images. Moreover, we gave evidence for the gener-
alizability of the CNN’s results by including two larger external142 https://doi.org/10.1016/j.annonc.2019.10.013datasets (one with full blinding of authors to true diagnoses)
in which the tested CNN showed comparable ROC AUCs.
There are several limitations to this study. First, current
deep learning algorithms lack interpretability;20 therefore,
we are unable to name specific causes for false classifica-
tions. Unfortunately, this lack of interpretability prevents
making changes for improvement, which leads to repeating
the same mistakes in the future. Secondly, to safeguard the
feasibility of the reader study our test set included 100 le-
sions, thus leaving only a few cases for certain diagnoses.
The CNN results attained in these diagnoses should,
therefore, be interpreted with caution. Thirdly, the compi-
lation of our test set did not include some other benign
(e.g. viral warts), malignant (e.g. Merkel cell carcinoma), or
inflammatory skin lesions (e.g. clear cell acanthoma).
Therefore, our results should not be generalized to a large
prospective patient population. Finally, the CNN was mostly
trained with dermoscopic images of patients with a
Caucasian genetic background and may not provide com-
parable results in a population of non-white skin types.
In conclusion, the results of our study demonstrate that
the tested CNN is capable of classifying a broad spectrum of
skin tumors at a high level of sensitivity and specificity.
Under less artificial conditions with clinical close-up images,
dermoscopic images, and textual case information for re-
view, the management decisions of most dermatologists
were either on or slightly above the level of the CNN. Ex-
perts in dermoscopy with access to relevant case informa-
tion commonly outperformed the CNN’s specificity at a
comparable sensitivity. There is a need for prospective
studies and an improved interpretability of the CNN’s clas-
sification results to take this research to the next level.ACKNOWLEDGEMENTS
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